The global Artificial Intelligence Drug R&D market size was valued at US$ 603.6 million in 2023. With growing demand in downstream market, the Artificial Intelligence Drug R&D is forecast to a readjusted size of US$ 1097.8 million by 2030 with a CAGR of 8.9% during review period.
The research report highlights the growth potential of the global Artificial Intelligence Drug R&D market. Artificial Intelligence Drug R&D are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Artificial Intelligence Drug R&D. 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Artificial Intelligence Drug R&D market.
Artificial Intelligence Drug R&D means that we use AI (narrow AI for now, which specilizing in few tasks) to generate and analyse immense amounts of biological and outcomes data from patients or chem database to predict new targets, or to conclude standard models.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Artificial Intelligence Drug R&D market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the Artificial Intelligence Drug R&D market. It may include historical data, market segmentation by Type (e.g., AI Platfrom, Analytics Service), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Artificial Intelligence Drug R&D market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Artificial Intelligence Drug R&D market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Artificial Intelligence Drug R&D industry. This include advancements in Artificial Intelligence Drug R&D technology, Artificial Intelligence Drug R&D new entrants, Artificial Intelligence Drug R&D new investment, and other innovations that are shaping the future of Artificial Intelligence Drug R&D.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Artificial Intelligence Drug R&D market. It includes factors influencing customer ' purchasing decisions, preferences for Artificial Intelligence Drug R&D product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Artificial Intelligence Drug R&D market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Artificial Intelligence Drug R&D market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Artificial Intelligence Drug R&D market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Artificial Intelligence Drug R&D industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Artificial Intelligence Drug R&D market.
麻豆原创 Segmentation:
Artificial Intelligence Drug R&D market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
AI Platfrom
Analytics Service
Segmentation by application
Drug Discovery
Precision Medicine
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
IBM Watson
BioXel
Insilico Medicine
Gatehouse Bio
Google DeepMind
Genpact Cora
Cyclica Inc
QuantumBlack
Nq Medical
Phenomic AI
Palantir Technologies
BenevolentAI
Atomwise
Numerate
Recursion Pharmaceuticals
Exscientia
TwoXAR
AiCure
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Artificial Intelligence Drug R&D 麻豆原创 Size 2019-2030
2.1.2 Artificial Intelligence Drug R&D 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Artificial Intelligence Drug R&D Segment by Type
2.2.1 AI Platfrom
2.2.2 Analytics Service
2.3 Artificial Intelligence Drug R&D 麻豆原创 Size by Type
2.3.1 Artificial Intelligence Drug R&D 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Artificial Intelligence Drug R&D 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Artificial Intelligence Drug R&D Segment by Application
2.4.1 Drug Discovery
2.4.2 Precision Medicine
2.5 Artificial Intelligence Drug R&D 麻豆原创 Size by Application
2.5.1 Artificial Intelligence Drug R&D 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Artificial Intelligence Drug R&D 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Artificial Intelligence Drug R&D 麻豆原创 Size by Player
3.1 Artificial Intelligence Drug R&D 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global Artificial Intelligence Drug R&D Revenue by Players (2019-2024)
3.1.2 Global Artificial Intelligence Drug R&D Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Artificial Intelligence Drug R&D Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Artificial Intelligence Drug R&D by Regions
4.1 Artificial Intelligence Drug R&D 麻豆原创 Size by Regions (2019-2024)
4.2 Americas Artificial Intelligence Drug R&D 麻豆原创 Size Growth (2019-2024)
4.3 APAC Artificial Intelligence Drug R&D 麻豆原创 Size Growth (2019-2024)
4.4 Europe Artificial Intelligence Drug R&D 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa Artificial Intelligence Drug R&D 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Artificial Intelligence Drug R&D 麻豆原创 Size by Country (2019-2024)
5.2 Americas Artificial Intelligence Drug R&D 麻豆原创 Size by Type (2019-2024)
5.3 Americas Artificial Intelligence Drug R&D 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Artificial Intelligence Drug R&D 麻豆原创 Size by Region (2019-2024)
6.2 APAC Artificial Intelligence Drug R&D 麻豆原创 Size by Type (2019-2024)
6.3 APAC Artificial Intelligence Drug R&D 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Artificial Intelligence Drug R&D by Country (2019-2024)
7.2 Europe Artificial Intelligence Drug R&D 麻豆原创 Size by Type (2019-2024)
7.3 Europe Artificial Intelligence Drug R&D 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Artificial Intelligence Drug R&D by Region (2019-2024)
8.2 Middle East & Africa Artificial Intelligence Drug R&D 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Artificial Intelligence Drug R&D 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Artificial Intelligence Drug R&D 麻豆原创 Forecast
10.1 Global Artificial Intelligence Drug R&D Forecast by Regions (2025-2030)
10.1.1 Global Artificial Intelligence Drug R&D Forecast by Regions (2025-2030)
10.1.2 Americas Artificial Intelligence Drug R&D Forecast
10.1.3 APAC Artificial Intelligence Drug R&D Forecast
10.1.4 Europe Artificial Intelligence Drug R&D Forecast
10.1.5 Middle East & Africa Artificial Intelligence Drug R&D Forecast
10.2 Americas Artificial Intelligence Drug R&D Forecast by Country (2025-2030)
10.2.1 United States Artificial Intelligence Drug R&D 麻豆原创 Forecast
10.2.2 Canada Artificial Intelligence Drug R&D 麻豆原创 Forecast
10.2.3 Mexico Artificial Intelligence Drug R&D 麻豆原创 Forecast
10.2.4 Brazil Artificial Intelligence Drug R&D 麻豆原创 Forecast
10.3 APAC Artificial Intelligence Drug R&D Forecast by Region (2025-2030)
10.3.1 China Artificial Intelligence Drug R&D 麻豆原创 Forecast
10.3.2 Japan Artificial Intelligence Drug R&D 麻豆原创 Forecast
10.3.3 Korea Artificial Intelligence Drug R&D 麻豆原创 Forecast
10.3.4 Southeast Asia Artificial Intelligence Drug R&D 麻豆原创 Forecast
10.3.5 India Artificial Intelligence Drug R&D 麻豆原创 Forecast
10.3.6 Australia Artificial Intelligence Drug R&D 麻豆原创 Forecast
10.4 Europe Artificial Intelligence Drug R&D Forecast by Country (2025-2030)
10.4.1 Germany Artificial Intelligence Drug R&D 麻豆原创 Forecast
10.4.2 France Artificial Intelligence Drug R&D 麻豆原创 Forecast
10.4.3 UK Artificial Intelligence Drug R&D 麻豆原创 Forecast
10.4.4 Italy Artificial Intelligence Drug R&D 麻豆原创 Forecast
10.4.5 Russia Artificial Intelligence Drug R&D 麻豆原创 Forecast
10.5 Middle East & Africa Artificial Intelligence Drug R&D Forecast by Region (2025-2030)
10.5.1 Egypt Artificial Intelligence Drug R&D 麻豆原创 Forecast
10.5.2 South Africa Artificial Intelligence Drug R&D 麻豆原创 Forecast
10.5.3 Israel Artificial Intelligence Drug R&D 麻豆原创 Forecast
10.5.4 Turkey Artificial Intelligence Drug R&D 麻豆原创 Forecast
10.5.5 GCC Countries Artificial Intelligence Drug R&D 麻豆原创 Forecast
10.6 Global Artificial Intelligence Drug R&D Forecast by Type (2025-2030)
10.7 Global Artificial Intelligence Drug R&D Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 IBM Watson
11.1.1 IBM Watson Company Information
11.1.2 IBM Watson Artificial Intelligence Drug R&D Product Offered
11.1.3 IBM Watson Artificial Intelligence Drug R&D Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 IBM Watson Main Business Overview
11.1.5 IBM Watson Latest Developments
11.2 BioXel
11.2.1 BioXel Company Information
11.2.2 BioXel Artificial Intelligence Drug R&D Product Offered
11.2.3 BioXel Artificial Intelligence Drug R&D Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 BioXel Main Business Overview
11.2.5 BioXel Latest Developments
11.3 Insilico Medicine
11.3.1 Insilico Medicine Company Information
11.3.2 Insilico Medicine Artificial Intelligence Drug R&D Product Offered
11.3.3 Insilico Medicine Artificial Intelligence Drug R&D Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Insilico Medicine Main Business Overview
11.3.5 Insilico Medicine Latest Developments
11.4 Gatehouse Bio
11.4.1 Gatehouse Bio Company Information
11.4.2 Gatehouse Bio Artificial Intelligence Drug R&D Product Offered
11.4.3 Gatehouse Bio Artificial Intelligence Drug R&D Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Gatehouse Bio Main Business Overview
11.4.5 Gatehouse Bio Latest Developments
11.5 Google DeepMind
11.5.1 Google DeepMind Company Information
11.5.2 Google DeepMind Artificial Intelligence Drug R&D Product Offered
11.5.3 Google DeepMind Artificial Intelligence Drug R&D Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Google DeepMind Main Business Overview
11.5.5 Google DeepMind Latest Developments
11.6 Genpact Cora
11.6.1 Genpact Cora Company Information
11.6.2 Genpact Cora Artificial Intelligence Drug R&D Product Offered
11.6.3 Genpact Cora Artificial Intelligence Drug R&D Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Genpact Cora Main Business Overview
11.6.5 Genpact Cora Latest Developments
11.7 Cyclica Inc
11.7.1 Cyclica Inc Company Information
11.7.2 Cyclica Inc Artificial Intelligence Drug R&D Product Offered
11.7.3 Cyclica Inc Artificial Intelligence Drug R&D Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Cyclica Inc Main Business Overview
11.7.5 Cyclica Inc Latest Developments
11.8 QuantumBlack
11.8.1 QuantumBlack Company Information
11.8.2 QuantumBlack Artificial Intelligence Drug R&D Product Offered
11.8.3 QuantumBlack Artificial Intelligence Drug R&D Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 QuantumBlack Main Business Overview
11.8.5 QuantumBlack Latest Developments
11.9 Nq Medical
11.9.1 Nq Medical Company Information
11.9.2 Nq Medical Artificial Intelligence Drug R&D Product Offered
11.9.3 Nq Medical Artificial Intelligence Drug R&D Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Nq Medical Main Business Overview
11.9.5 Nq Medical Latest Developments
11.10 Phenomic AI
11.10.1 Phenomic AI Company Information
11.10.2 Phenomic AI Artificial Intelligence Drug R&D Product Offered
11.10.3 Phenomic AI Artificial Intelligence Drug R&D Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Phenomic AI Main Business Overview
11.10.5 Phenomic AI Latest Developments
11.11 Palantir Technologies
11.11.1 Palantir Technologies Company Information
11.11.2 Palantir Technologies Artificial Intelligence Drug R&D Product Offered
11.11.3 Palantir Technologies Artificial Intelligence Drug R&D Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 Palantir Technologies Main Business Overview
11.11.5 Palantir Technologies Latest Developments
11.12 BenevolentAI
11.12.1 BenevolentAI Company Information
11.12.2 BenevolentAI Artificial Intelligence Drug R&D Product Offered
11.12.3 BenevolentAI Artificial Intelligence Drug R&D Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.12.4 BenevolentAI Main Business Overview
11.12.5 BenevolentAI Latest Developments
11.13 Atomwise
11.13.1 Atomwise Company Information
11.13.2 Atomwise Artificial Intelligence Drug R&D Product Offered
11.13.3 Atomwise Artificial Intelligence Drug R&D Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.13.4 Atomwise Main Business Overview
11.13.5 Atomwise Latest Developments
11.14 Numerate
11.14.1 Numerate Company Information
11.14.2 Numerate Artificial Intelligence Drug R&D Product Offered
11.14.3 Numerate Artificial Intelligence Drug R&D Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.14.4 Numerate Main Business Overview
11.14.5 Numerate Latest Developments
11.15 Recursion Pharmaceuticals
11.15.1 Recursion Pharmaceuticals Company Information
11.15.2 Recursion Pharmaceuticals Artificial Intelligence Drug R&D Product Offered
11.15.3 Recursion Pharmaceuticals Artificial Intelligence Drug R&D Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.15.4 Recursion Pharmaceuticals Main Business Overview
11.15.5 Recursion Pharmaceuticals Latest Developments
11.16 Exscientia
11.16.1 Exscientia Company Information
11.16.2 Exscientia Artificial Intelligence Drug R&D Product Offered
11.16.3 Exscientia Artificial Intelligence Drug R&D Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.16.4 Exscientia Main Business Overview
11.16.5 Exscientia Latest Developments
11.17 TwoXAR
11.17.1 TwoXAR Company Information
11.17.2 TwoXAR Artificial Intelligence Drug R&D Product Offered
11.17.3 TwoXAR Artificial Intelligence Drug R&D Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.17.4 TwoXAR Main Business Overview
11.17.5 TwoXAR Latest Developments
11.18 AiCure
11.18.1 AiCure Company Information
11.18.2 AiCure Artificial Intelligence Drug R&D Product Offered
11.18.3 AiCure Artificial Intelligence Drug R&D Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.18.4 AiCure Main Business Overview
11.18.5 AiCure Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.